"The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is adminis"...
(Generic versions may still be available.)
Insulin allergy occurs very rarely, but when it does, it may cause a serious reaction including a general skin rash over the body, shortness of breath, fast pulse, sweating and a drop in blood pressure. If any of these symptoms develop you should seek emergency medical care. The formation of fatty lumps at the infusion site or injection site is usually a sign of frequent needle insertion at the same site. Remember to choose new infusion sites or injection sites at which to insert each new needle and consult with your physician or diabetes educator if you develop these fatty lumps at the infusion site. The skin at the infusion site or injection site may also become red, swollen and itchy. This is a local reaction. It may occur if needle insertion is not properly made at the infusion site or injection site, or as a result of skin sensitivity to the cleansing solutions or if the patient is allergic to insulin. If you have a local reaction, consult with your physician or diabetes educator. Patients with severe systemic allergic reactions to insulin (i.e. generalized urticaria, angioedema, anaphylaxis) should be skin tested with each new preparation to be used prior to initiation of therapy with that preparation.
Read the Velosulin (insulin human) Side Effects Center for a complete guide to possible side effects
No information provided.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/8/2004
Additional Velosulin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find tips and advances in treatment.